The Role of Measurable Residual Disease (MRD) at Time of Allogeneic Hematopoietic Cell Transplantation in Adults With Acute Lymphoblastic Leukemia Transplanted After Myeloablative Conditioning. A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2018.12.071
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia-A Survey From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

American Journal of Hematology
Hematology
2016English

Non-Myeloablative Conditioning With Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia

Haematologica
Hematology
2011English

Impact of Graft-Versus-Host Disease After Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

Post-Remission Strategies for the Prevention of Relapse Following Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia: Expert Review From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Bone Marrow Transplantation
TransplantationHematology
2018English

The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Measurable Residual Disease, Conditioning Regimen Intensity and Age Predict Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Remission: A Registry Analysis of 2292 Patients by the Acute Leukemia Working Party Eu

American Journal of Hematology
Hematology
2018English

Outcomes of Allogeneic Hematopoietic Cell Transplantation for AML With Complex Karyotypes: A Retrospective Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and MD Anderson Cancer Center

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- A Report From the Acute Leukemia Working Party of the EBMT

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Acute Myeloid Leukemia Over 70 Years of Age: On Behalf of the Acute Leukemia Working Party of the EBMT

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy